DE60335387D1 - Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen - Google Patents
Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellenInfo
- Publication number
- DE60335387D1 DE60335387D1 DE60335387T DE60335387T DE60335387D1 DE 60335387 D1 DE60335387 D1 DE 60335387D1 DE 60335387 T DE60335387 T DE 60335387T DE 60335387 T DE60335387 T DE 60335387T DE 60335387 D1 DE60335387 D1 DE 60335387D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- provasopressinexprimating
- targetting
- identification
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 206010006256 Breast hyperplasia Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 abstract 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39612102P | 2002-07-16 | 2002-07-16 | |
| PCT/US2003/022264 WO2004006860A2 (en) | 2002-07-16 | 2003-07-16 | Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60335387D1 true DE60335387D1 (de) | 2011-01-27 |
Family
ID=30115976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60335387T Expired - Lifetime DE60335387D1 (de) | 2002-07-16 | 2003-07-16 | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7790162B2 (de) |
| EP (1) | EP1539818B1 (de) |
| JP (1) | JP2006505510A (de) |
| AT (1) | ATE491727T1 (de) |
| AU (1) | AU2003251966A1 (de) |
| CA (1) | CA2492475A1 (de) |
| DE (1) | DE60335387D1 (de) |
| WO (1) | WO2004006860A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1628136A1 (de) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Diagnoseverfahren für Krankheiten unter Verwendung von Copeptin |
| DE102006050497A1 (de) * | 2006-10-26 | 2008-04-30 | Brahms Aktiengesellschaft | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
| EP2084543B1 (de) * | 2006-10-26 | 2017-10-18 | B.R.A.H.M.S GmbH | Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii |
| DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006058266A1 (de) * | 2006-12-08 | 2008-06-12 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin |
| WO2009137113A2 (en) * | 2008-05-09 | 2009-11-12 | Woomera Therapeutics, Inc. | Peptides, antibodies, and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| EP2356463B1 (de) * | 2008-10-31 | 2017-08-30 | B.R.A.H.M.S GmbH | Arginin-vasopressin-prohormon als vorhersagender biomarker für diabetes |
| US9841480B2 (en) | 2009-04-02 | 2017-12-12 | Regents Of The University Of Minnesota | Localization of magnetic particles by means of swift-MRI |
| US20140051183A1 (en) * | 2010-06-18 | 2014-02-20 | B.R.A.H.M.S Gmbh | Biomarkers for the prediction of incident cancer |
| EP2541252A1 (de) | 2011-06-30 | 2013-01-02 | B.R.A.H.M.S GmbH | Verfahren zum Erhalten eines Binders für Preprovasopressin oder Fragmente davon |
| CA2854467A1 (en) * | 2011-11-11 | 2013-05-16 | Woomera Therapeutics | Antagonists for abnormal vasopressin v2 receptor and uses thereof |
| WO2013071030A1 (en) * | 2011-11-11 | 2013-05-16 | Woomera Therapeutics | Provasopressin antagonists and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
-
2003
- 2003-07-16 AU AU2003251966A patent/AU2003251966A1/en not_active Abandoned
- 2003-07-16 WO PCT/US2003/022264 patent/WO2004006860A2/en active Application Filing
- 2003-07-16 EP EP03764750A patent/EP1539818B1/de not_active Expired - Lifetime
- 2003-07-16 CA CA002492475A patent/CA2492475A1/en not_active Abandoned
- 2003-07-16 DE DE60335387T patent/DE60335387D1/de not_active Expired - Lifetime
- 2003-07-16 US US10/521,091 patent/US7790162B2/en not_active Expired - Fee Related
- 2003-07-16 JP JP2004521917A patent/JP2006505510A/ja active Pending
- 2003-07-16 AT AT03764750T patent/ATE491727T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004006860A3 (en) | 2005-02-03 |
| AU2003251966A1 (en) | 2004-02-02 |
| CA2492475A1 (en) | 2004-01-22 |
| JP2006505510A (ja) | 2006-02-16 |
| US7790162B2 (en) | 2010-09-07 |
| ATE491727T1 (de) | 2011-01-15 |
| EP1539818A2 (de) | 2005-06-15 |
| WO2004006860A2 (en) | 2004-01-22 |
| EP1539818A4 (de) | 2006-11-08 |
| EP1539818B1 (de) | 2010-12-15 |
| US20080050376A1 (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nishimori et al. | Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin | |
| DE60335387D1 (de) | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen | |
| DE50106127D1 (de) | Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites | |
| WO2006047484A3 (en) | Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation | |
| DE60033555D1 (de) | Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden | |
| ATE505544T1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
| TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
| DE60130538D1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
| WO2009032949A3 (en) | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection | |
| Zhang et al. | Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients | |
| DE502005010086D1 (de) | Monoklonaler antikörper gegen humanen frizzled-4-rezeptor | |
| ATE459883T1 (de) | Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose | |
| DE60129151D1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
| DE602005023629D1 (de) | Biomarker für den frühzeitigen nachweis von ovarialkarzinom | |
| DE60137264D1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| TW200700089A (en) | Recombinant protein comprising starch binding domain and use thereof | |
| DK2054443T3 (da) | Antistoffer mod en epitop fra AGR2, assays og hybridomer | |
| WO2007020522A3 (en) | Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| Lyndin et al. | Invasive breast carcinoma of no special type with medullary pattern: morphological and immunohistochemical features | |
| Moul et al. | Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen | |
| DE60013093D1 (de) | Methoden und kits zum sequenzieren von polypeptiden | |
| Aggarwal et al. | Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer | |
| WO2003068268A3 (en) | Treatment, diagnosis and imaging of disease | |
| ATE440284T1 (de) | Verwendung von adiponectin zur diagnose von krebs |